Lidocaine nonclinical toxicology

Revision as of 15:58, 11 March 2014 by Ahmed Zaghw (talk | contribs) (→‎Nonclinical Toxicology)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Lidocaine
XYLOCAINE® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Lidocaine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility of Xylocaine have not been conducted.[1]

References

  1. "XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION [ASTRAZENECA LP]".

Adapted from the FDA Package Insert.